Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Oct 27, 2015 at 12:55 PM EDT

What to Look For in Gilead Earnings

Gilead Sciences is set to report its third-quarter financial results after the markets close on Thursday.

Jon C. Ogg | Oct 27, 2015 at 11:50 AM EDT

After HCA Earnings, Should Hospitals Use Cash for Stock Buybacks?

HCA is out with earnings, but there is a serious question here when it comes to the greater good: should…

Jon C. Ogg | Oct 27, 2015 at 10:05 AM EDT

How Pfizer Stacks Up Against Merck on Earnings

Pfizer and Merck both released their third-quarter earnings on Tuesday morning. So, which drug giant is looking better after earnings?

Chris Lange | Oct 27, 2015 at 9:05 AM EDT

Short Sellers Have Mixed Views on Major Pharma

The October 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical…

Chris Lange | Oct 27, 2015 at 8:10 AM EDT

Short Sellers Become More Selective on Leading Biotechs

The October 15 short interest data have been compared with the previous figures, and short interest mixed in these selected…

Chris Lange | Oct 26, 2015 at 3:25 PM EDT

What to Look For in Pfizer’s Earnings

Pfizer is scheduled to release its third-quarter financial results before the markets open on Tuesday.

Chris Lange | Oct 26, 2015 at 1:50 PM EDT

What to Expect From Merck Earnings

Merckis expected to report its third-quarter financial results before the markets open on Tuesday.

Chris Lange | Oct 26, 2015 at 8:45 AM EDT

How an FDA Approval Changes the Game for Endo and BioDelivery Sciences

Endo International and BioDelivery Sciences have announced that the U.S. Food and Drug Administration (FDA) approved their long-term opioid treatment,…

Chris Lange | Oct 24, 2015 at 9:40 AM EDT

8 BioPharma Movers That Cannot Be Ignored

These biotech stocks 24/7 Wall St. has picked stood out from the rest with at least 25% gains over the…

Chris Lange | Oct 23, 2015 at 4:09 PM EDT

Janssen Secures Approval From FDA on New LPS and LMS Drug

ThinkstockJanssen Biotech announced that the U.S. Food and Drug Administration (FDA) approved Yondelis (trabectedin) for the treatment of patients with…

Chris Lange | Oct 23, 2015 at 2:36 PM EDT

Centene Receives Overwhelming Approval to Acquire Health Net

ThinkstockFollowing a special shareholder meeting in St. Louis, Centene Corporation (NYSE: CNC) announced that its shareholders voted overwhelmingly to approve…

Chris Lange | Oct 23, 2015 at 1:35 PM EDT

Why Amgen’s Future Is Looking Bright

Amgen is slowly getting closer to an FDA final decision for its first-of-a-kind cancer therapy, talimogene laherparepvec (T-Vec).

Paul Ausick | Oct 23, 2015 at 11:10 AM EDT

Drug Company to Offer $750 Pill for $1

On Thursday when a generic drug company based in San Diego said it will produce an alternative to the $750…

Lee Jackson | Oct 23, 2015 at 8:35 AM EDT

4 Top Merrill Lynch Dividend-Paying Pharmaceutical Stocks to Buy Now

24/7 Wall St. screened the Merrill Lynch research universe for pharmaceutical stocks paying solid dividends that are rated Buy, and…

Chris Lange | Oct 22, 2015 at 4:31 PM EDT

How FDA Warning Could Spell Disaster for AbbVie and Opportunity for Gilead

ThinkstockThe U.S. Food and Drug Administration (FDA) issued a warning that hepatitis C treatments, Viekira Pak and Technivie, can cause…

1 … 237 238 239 240 241 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

What to Look For in Gilead Earnings

After HCA Earnings, Should Hospitals Use Cash for Stock Buybacks?

How Pfizer Stacks Up Against Merck on Earnings

Short Sellers Have Mixed Views on Major Pharma

Short Sellers Become More Selective on Leading Biotechs

What to Look For in Pfizer’s Earnings

What to Expect From Merck Earnings

How an FDA Approval Changes the Game for Endo and BioDelivery Sciences

8 BioPharma Movers That Cannot Be Ignored

Janssen Secures Approval From FDA on New LPS and LMS Drug

Centene Receives Overwhelming Approval to Acquire Health Net

Why Amgen’s Future Is Looking Bright

Drug Company to Offer $750 Pill for $1

4 Top Merrill Lynch Dividend-Paying Pharmaceutical Stocks to Buy Now

How FDA Warning Could Spell Disaster for AbbVie and Opportunity for Gilead

U.S. Navy intercepts Iranian cruise missiles — 4 defense stocks to watch today

AMZW’s Weekly Payouts Drop 79% as Volatility Collapses; Can Investors Count on Them?

The Reverse Mortgage Line of Credit That Grows Untouched for 15 Years and Becomes a $700,000 Liquidity Buffer at 80

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

U.S. Navy intercepts Iranian cruise missiles — 4 defense stocks to watch today

AMZW’s Weekly Payouts Drop 79% as Volatility Collapses; Can Investors Count on Them?

Health and Healthcare Articles

All Health and Healthcare Articles

What to Look For in Gilead Earnings

After HCA Earnings, Should Hospitals Use Cash for Stock Buybacks?

How Pfizer Stacks Up Against Merck on Earnings

Short Sellers Have Mixed Views on Major Pharma

Short Sellers Become More Selective on Leading Biotechs

What to Look For in Pfizer’s Earnings

What to Expect From Merck Earnings

How an FDA Approval Changes the Game for Endo and BioDelivery Sciences

8 BioPharma Movers That Cannot Be Ignored

Janssen Secures Approval From FDA on New LPS and LMS Drug

Centene Receives Overwhelming Approval to Acquire Health Net

Why Amgen’s Future Is Looking Bright

Drug Company to Offer $750 Pill for $1

4 Top Merrill Lynch Dividend-Paying Pharmaceutical Stocks to Buy Now

How FDA Warning Could Spell Disaster for AbbVie and Opportunity for Gilead

U.S. Navy intercepts Iranian cruise missiles — 4 defense stocks to watch today

AMZW’s Weekly Payouts Drop 79% as Volatility Collapses; Can Investors Count on Them?

The Reverse Mortgage Line of Credit That Grows Untouched for 15 Years and Becomes a $700,000 Liquidity Buffer at 80

Featured Reads

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how